In a update to investors, scPharmaceuticals (SCPH -0.6%) says that it remains on schedule to resubmit its U.S. marketing application for lead candidate FUROSCIX for the treatment of congestion in heart failure patients by mid-2020.
FUROSCIX is pH-neutral solution of a diuretic called furosemide that is administered via subcutaneous infusion by a wearable injector that is part of an integrated drug delivery system.
On another note, it has secured a new four-year $20M term loan facility from Solar Capital Ltd. and Silicon Valley Bank. It drew the funds at closing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.